FindTrial
Sign In

A phase III, randomised, double blind, multicentre study to evaluate the safety and efficacy of dalbavancin versus linezolid in the treatment of complicated skin and soft tissue infections with suspected gram-positive bacterial pathogens

A phase III, randomised, double blind, multicentre study to evaluate the safety and efficacy of dalbavancin versus linezolid in the treatment of complicated skin and soft tissue infections with suspected gram-positive bacterial pathogens

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN63718248
Enrollment
Unknown
Registered
2004-09-30
Start date
2003-09-30
Completion date
Unknown
Last updated
2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infections and Infestations: Gram-positive bacterial pathogens Infections and Infestations Gram-positive bacterial pathogens

Interventions

Dalbavancin vs standard care

Sponsors

Department of Health
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients having infection consistent with complicated skin and soft tissue infection either involving deeper soft tissue or requiring significant surgical intervention 2. Patients to require 24hrs of parental therapy for suspected gram-positive complicated skin

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
The clinical and microbiological responses to therapy.—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026